vs
Bioceres Crop Solutions Corp.（BIOX）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
Bioceres Crop Solutions Corp.的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.0倍（$77.6M vs $75.5M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs -16.8%），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs -8.4%）
Bioceres Crop Solutions Corp是一家全球农业科技企业，研发并商业化耐旱种子性状、生物肥料、生物农药等可持续作物增产解决方案，服务南美、北美、欧洲及亚太地区的农户，致力于提升作物产量，同时降低农业生产的环境影响。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
BIOX vs PBYI — 直观对比
营收规模更大
BIOX
是对方的1.0倍
$75.5M
营收增速更快
PBYI
高出44.5%
-16.8%
两年增速更快
PBYI
近两年复合增速
-8.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $77.6M | $75.5M |
| 净利润 | $-7.4M | — |
| 毛利率 | 46.8% | 69.3% |
| 营业利润率 | 9.3% | 22.7% |
| 净利率 | -9.6% | — |
| 营收同比 | -16.8% | 27.7% |
| 净利润同比 | -20.2% | — |
| 每股收益（稀释后） | $-0.12 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIOXPBYI
| Q4 25 | — | $75.5M | ||
| Q3 25 | $77.6M | $54.5M | ||
| Q2 25 | — | $52.4M | ||
| Q1 25 | $60.6M | $46.0M | ||
| Q4 24 | $98.8M | $59.1M | ||
| Q3 24 | $93.3M | $80.5M | ||
| Q2 24 | — | $47.1M | ||
| Q1 24 | $84.0M | $43.8M |
净利润BIOXPBYI
| Q4 25 | — | — | ||
| Q3 25 | $-7.4M | $8.8M | ||
| Q2 25 | — | $5.9M | ||
| Q1 25 | $-1.6M | $3.0M | ||
| Q4 24 | $605.2K | — | ||
| Q3 24 | $-6.2M | $20.3M | ||
| Q2 24 | — | $-4.5M | ||
| Q1 24 | $9.8M | $-4.8M |
毛利率BIOXPBYI
| Q4 25 | — | 69.3% | ||
| Q3 25 | 46.8% | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | 39.4% | 77.1% | ||
| Q4 24 | 42.0% | 76.4% | ||
| Q3 24 | 40.2% | 63.9% | ||
| Q2 24 | — | 77.4% | ||
| Q1 24 | 50.8% | 75.5% |
营业利润率BIOXPBYI
| Q4 25 | — | 22.7% | ||
| Q3 25 | 9.3% | 17.6% | ||
| Q2 25 | — | 12.7% | ||
| Q1 25 | 1.5% | 8.7% | ||
| Q4 24 | 14.5% | 22.6% | ||
| Q3 24 | 2.5% | 27.4% | ||
| Q2 24 | — | -4.6% | ||
| Q1 24 | 15.7% | -5.3% |
净利率BIOXPBYI
| Q4 25 | — | — | ||
| Q3 25 | -9.6% | 16.2% | ||
| Q2 25 | — | 11.2% | ||
| Q1 25 | -2.6% | 6.5% | ||
| Q4 24 | 0.6% | — | ||
| Q3 24 | -6.6% | 25.2% | ||
| Q2 24 | — | -9.6% | ||
| Q1 24 | 11.6% | -11.0% |
每股收益（稀释后）BIOXPBYI
| Q4 25 | — | $0.26 | ||
| Q3 25 | $-0.12 | $0.17 | ||
| Q2 25 | — | $0.12 | ||
| Q1 25 | $-0.02 | $0.06 | ||
| Q4 24 | $0.00 | $0.40 | ||
| Q3 24 | $-0.10 | $0.41 | ||
| Q2 24 | — | $-0.09 | ||
| Q1 24 | $0.14 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $15.5M | $97.5M |
| 总债务越低越好 | — | $22.7M |
| 股东权益账面价值 | $288.3M | $130.3M |
| 总资产 | $734.9M | $216.3M |
| 负债/权益比越低杠杆越低 | — | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资BIOXPBYI
| Q4 25 | — | $97.5M | ||
| Q3 25 | $15.5M | $94.4M | ||
| Q2 25 | — | $96.0M | ||
| Q1 25 | $38.5M | $93.2M | ||
| Q4 24 | $29.2M | $101.0M | ||
| Q3 24 | $32.3M | $96.7M | ||
| Q2 24 | — | $96.8M | ||
| Q1 24 | $16.4M | $107.2M |
总债务BIOXPBYI
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
股东权益BIOXPBYI
| Q4 25 | — | $130.3M | ||
| Q3 25 | $288.3M | $115.3M | ||
| Q2 25 | — | $104.7M | ||
| Q1 25 | $345.0M | $97.1M | ||
| Q4 24 | $346.3M | $92.1M | ||
| Q3 24 | $346.0M | $71.1M | ||
| Q2 24 | — | $48.5M | ||
| Q1 24 | $348.5M | $51.0M |
总资产BIOXPBYI
| Q4 25 | — | $216.3M | ||
| Q3 25 | $734.9M | $202.9M | ||
| Q2 25 | — | $194.9M | ||
| Q1 25 | $798.2M | $196.2M | ||
| Q4 24 | $835.2M | $213.3M | ||
| Q3 24 | $827.3M | $220.7M | ||
| Q2 24 | — | $205.0M | ||
| Q1 24 | $836.1M | $214.1M |
负债/权益比BIOXPBYI
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | — | $14.4M |
| 自由现金流率自由现金流/营收 | — | 19.1% |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $41.7M |
8季度趋势，按日历期对齐
经营现金流BIOXPBYI
| Q4 25 | — | $14.4M | ||
| Q3 25 | $14.4M | $9.7M | ||
| Q2 25 | — | $14.1M | ||
| Q1 25 | $23.3M | $3.6M | ||
| Q4 24 | $-5.4M | $15.6M | ||
| Q3 24 | $5.2M | $11.0M | ||
| Q2 24 | — | $1.0M | ||
| Q1 24 | $-17.4M | $11.2M |
自由现金流BIOXPBYI
| Q4 25 | — | $14.4M | ||
| Q3 25 | — | $9.7M | ||
| Q2 25 | — | $14.1M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | — | $11.0M | ||
| Q2 24 | — | $1.0M | ||
| Q1 24 | — | — |
自由现金流率BIOXPBYI
| Q4 25 | — | 19.1% | ||
| Q3 25 | — | 17.7% | ||
| Q2 25 | — | 26.8% | ||
| Q1 25 | — | 7.7% | ||
| Q4 24 | — | 26.4% | ||
| Q3 24 | — | 13.7% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | — |
资本支出强度BIOXPBYI
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
现金转化率BIOXPBYI
| Q4 25 | — | — | ||
| Q3 25 | — | 1.10× | ||
| Q2 25 | — | 2.41× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | -8.85× | — | ||
| Q3 24 | — | 0.54× | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.78× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
